Glossary
As you read the manual “Accelerating Clinical Trials: Best Practices for Recruitment
and Retention,” please refer to this list for definitions of terms that may be unfamiliar.
DaTscans™ Hoehn and Yahr Scale
DaTscan is a specialized imaging
technique that uses small amounts
of a radioactive drug to evaluate the
dopamine-producing cells in the brain.
By itself, it cannot diagnose Parkinson’s,
but it can help confirm a doctor’s
diagnosis. DaTscan is being studied as a
possible biomarker of Parkinson’s. The Hoehn and Yahr (H&Y) scale divides
PD into stages based on the severity of
motor symptoms. Clinical trials often
include H&Y stages as part of their
eligibility criteria so that they can ensure
that the intervention evaluated will
include people with the right symptoms.
Electronic Patient Reported
Outcomes (ePROs) An independent committee of scientists,
doctors and others (usually at least one
“non-scientific” person who represents
the patient voice) that evaluates and
approves each study’s protocol and
informed consent document, and
monitors ongoing study activities. The
Institutional Review Board (IRB) is in
place to protect the rights and welfare of
people participating in a study.
Data that is provided directly by
participants using electronic means such
as smartwatches, sensors and monitors.
These data complement traditional
measures used during in-person clinical
trial and study visits to give researchers a
more complete picture of disease.
Institutional Review Board (IRB)
Organic Marketing
A term in marketing that refers to the act
of generating attention for and driving
customers to a product or service without
the use of any paid advertisements.
42
Accelerating Clinical Trials: Best Practices for Recruitment and Retention